Preclinical development of [18F]TAAR1-2203 as a PET radioligand for imaging TAAR1 expression and receptor occupancy
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-025-07564-w ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Achi Haider und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Division of Nuclear Medicine and Molecular Imaging Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, …. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Fluorine Radioisotopes, Receptors, G-Protein-Coupled, Gene Expression Regulation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.
Abstract (Originalsprache)
Purpose
Trace amine-associated receptor 1 (TAAR1) is an emerging therapeutic target with various implications in neuropsychiatric and metabolic disorders. However, the absence of a suitable positron emission tomography (PET) radioligand has precluded non-invasive quantification of TAAR1 expression and drug-receptor interactions in vivo. In this study, we report the preclinical development of [ 18 F]TAAR1-2203, a fluorine-18 labeled PET ligand suitable to image TAAR1 expression in peripheral tissues. Methods [ 18 F]TAAR1-2203 ([ 18 F]RO5263397) was obtained via copper-mediated radiofluorination. In vitro stability was assessed in formulation, serum and using liver microsomes. Specific binding was evaluated by in vitro autoradiography, ex vivo biodistribution, and PET imaging under baseline and blockade conditions with structurally distinct TAAR1 agonists, as well as in TAAR1 knockout (KO) mice. Receptor occupancy studies were conducted in the pancreas – a peripheral organ with high physiological TAAR1 expression.
Results
TAAR1-2203 exhibited high TAAR1 affinity in competition binding assays across species, with K i values of 0.9 nM (mouse) and 5.7 nM (human). Tracer stability was corroborated by cross-species microsomal incubations and ex vivo radiometabolite analyses in mice. In peripheral tissues with known TAAR1 expression, [ 18 F]TAAR1-2203 displayed robust signal intensity that was significantly reduced under pharmacological blockade or in TAAR1 KO mice, thus confirming specific receptor binding. Although [ 18 F]TAAR1-2203 appeared to cross the blood-brain barrier based on brain time-activity curves and ex vivo radiometabolite analysis, no specific binding was observed in the CNS. Target occupancy studies in the pancreas demonstrated dose-dependent blockade, with a calculated D 50 of 0.67 µmol/kg for a structurally distinct potent TAAR1 agonist. Conclusion [ 18 F]TAAR1-2203 represents the first PET radioligand for TAAR1 imaging with favorable in vitro and in vivo performance characteristics, enabling non-invasive assessment of receptor expression and drug occupancy in peripheral TAAR1-expressing tissues. [ 18 F]TAAR1-2203 holds promise for translational application in various drug development programs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Division of Nuclear Medicine and Molecular Imaging Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, 02114, Boston, MA, USA.
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070, Basel, Switzerland.
- Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, 30322, Atlanta, GA, USA.
- Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Institute of Pharmaceutical Sciences ETH, Vladimir-Prelog-Weg 4, 8093, Zurich, Switzerland.
- Department of Radiology, Division of Nuclear Medicine and Molecular Imaging Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, 02114, Boston, MA, USA. steven.liang@emory.edu.
Förderung
- NIH HHS
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Haider, A., Xiao, Z., Chen, J., Pfister, S. K., Zhou, X., Li, Y., Chaudhary, A., Zhao, C., Rong, J., Paehler, A., Mohr, S., Norcross, R. D., Honer, M., Mu, L., Gobbi, L., Schibli, R., Hoener, M. C., & Liang, S. H. (2026). Preclinical development of [18F]TAAR1-2203 as a PET radioligand for imaging TAAR1 expression and receptor occupancy. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07564-w
Vancouver
Haider A, Xiao Z, Chen J, Pfister SK, Zhou X, Li Y, et al. Preclinical development of [18F]TAAR1-2203 as a PET radioligand for imaging TAAR1 expression and receptor occupancy. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07564-w
BibTeX
@article{Haider2026,
author = {Haider, Achi and Xiao, Zhiwei and Chen, Jiahui and Pfister, Stefanie K and Zhou, Xin and Li, Yinlong and Chaudhary, Ahmad and Zhao, Chunyu and Rong, Jian and Paehler, Axel and Mohr, Susanne and Norcross, Roger D and Honer, Michael and Mu, Linjing and Gobbi, Luca and Schibli, Roger and Hoener, Marius C and Liang, Steven H},
title = {Preclinical development of [18F]TAAR1-2203 as a PET radioligand for imaging TAAR1 expression and receptor occupancy},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-025-07564-w}
}
EUVIMED